loading
Immutep Limited Adr stock is traded at $1.77, with a volume of 103.55K. It is up +4.12% in the last 24 hours and up +0.57% over the past month. Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
See More
Previous Close:
$1.70
Open:
$1.75
24h Volume:
103.55K
Relative Volume:
0.74
Market Cap:
$260.53M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-7.8772
EPS:
-0.2247
Net Cash Flow:
-
1W Performance:
-6.35%
1M Performance:
+0.57%
6M Performance:
-2.75%
1Y Performance:
-9.23%
1-Day Range:
Value
$1.75
$1.8183
1-Week Range:
Value
$1.67
$2.08
52-Week Range:
Value
$1.32
$2.71

Immutep Limited Adr Stock (IMMP) Company Profile

Name
Name
Immutep Limited Adr
Name
Phone
-
Name
Address
-
Name
Employee
51
Name
Twitter
Name
Next Earnings Date
2025-12-03
Name
Latest SEC Filings
Name
IMMP's Discussions on Twitter

Compare IMMP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IMMP
Immutep Limited Adr
1.77 250.23M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.26 117.50B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
722.83 76.06B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.56 62.53B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
916.31 56.75B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
205.04 44.10B 447.02M -1.18B -906.14M -6.1812

Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades

Date Action Analyst Rating Change
May-17-24 Initiated CapitalOne Overweight
Aug-03-23 Initiated Robert W. Baird Outperform
Aug-03-21 Initiated Ladenburg Thalmann Buy
Jul-16-21 Resumed Maxim Group Buy
Sep-28-18 Initiated B. Riley FBR Buy
Feb-15-18 Reiterated Maxim Group Buy
View All

Immutep Limited Adr Stock (IMMP) Latest News

pulisher
Nov 14, 2025

[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC FilingForm 6-K - Stock Titan

Nov 14, 2025
pulisher
Oct 25, 2025

Immutep Limited Announces 2025 AGM with Key Resolutions - MSN

Oct 25, 2025
pulisher
Oct 24, 2025

IMMP 20-F highlights: pipeline progress, IFRS results, Nasdaq ADSs - Stock Titan

Oct 24, 2025
pulisher
Oct 21, 2025

Immutep reports Phase II neoadjuvant efti success in sarcoma via 6-K - Stock Titan

Oct 21, 2025
pulisher
Oct 14, 2025

Immutep Completes FDA Project Optimus, Advances Cancer Immunotherapy - MSN

Oct 14, 2025
pulisher
Oct 14, 2025

Immutep files 6-K with exhibit on FDA Project Optimus completion - Stock Titan

Oct 14, 2025
pulisher
Oct 13, 2025

Immutep Announces Successful Completion of FDA Project Optimus Requirements - The Manila Times

Oct 13, 2025
pulisher
Sep 19, 2025

Is Immutep Limited Depositary Receipt stock ready for a breakoutPortfolio Value Summary & Daily Volume Surge Signals - newser.com

Sep 19, 2025
pulisher
Sep 16, 2025

Reversal indicators forming on Immutep Limited Depositary Receipt stockMarket Activity Summary & Safe Entry Point Alerts - newser.com

Sep 16, 2025
pulisher
Sep 14, 2025

What momentum shifts mean for Immutep Limited Depositary Receipt2025 Bull vs Bear & AI Forecasted Stock Moves - newser.com

Sep 14, 2025
pulisher
Sep 08, 2025

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 - GlobeNewswire Inc.

Sep 08, 2025
pulisher
Sep 04, 2025

Immutep Limited Depositary Receipt Stock Lags Behind Sector BenchmarksMarket Performance Report & Weekly Setup with High ROI Potential - beatles.ru

Sep 04, 2025
pulisher
Aug 17, 2025

Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa - Yahoo Finance

Aug 17, 2025
pulisher
Aug 16, 2025

12 Best Australian Stocks to Buy Right Now - Insider Monkey

Aug 16, 2025
pulisher
Aug 04, 2025

Immutep Gains FDA Support for Cancer Therapy Development - TipRanks

Aug 04, 2025
pulisher
Jul 25, 2025

Is Immutep Limited Depositary Receipt a good long term investmentFree Stock Market Return Analysis - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 19, 2025

Immutep Limited Depositary Receipt Stock Analysis and ForecastExceptional gains - jammulinksnews.com

Jul 19, 2025
pulisher
Jun 15, 2025

Millennium Management LLC Sells 19,242 Shares of Immutep Limited (NASDAQ:IMMP) - Defense World

Jun 15, 2025
pulisher
Jun 08, 2025

Jane Street Group LLC Has $98,000 Position in Immutep Limited (NASDAQ:IMMP) - Defense World

Jun 08, 2025
pulisher
Jun 01, 2025

Immutep Ltd Highlights Immune System Innovations at Healthcare Conference - TipRanks

Jun 01, 2025
pulisher
May 06, 2025

Immutep stock soars on promising trial results By Investing.com - Investing.com Australia

May 06, 2025
pulisher
May 05, 2025

Immutep stock soars on promising trial results - Investing.com

May 05, 2025
pulisher
Apr 28, 2025

Immutep Advances Cancer Trials with Promising Developments - TipRanks

Apr 28, 2025
pulisher
Feb 11, 2025

Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now? - AInvest

Feb 11, 2025
pulisher
Dec 17, 2024

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewswire

Dec 17, 2024
pulisher
Jun 27, 2024

Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com

Jun 27, 2024
pulisher
Apr 18, 2024

Immutep appoints research institute to conduct first-in-human study of IMP761 - Biotech Dispatch

Apr 18, 2024
pulisher
Mar 06, 2024

symbol__ Stock Quote Price and Forecast - CNN

Mar 06, 2024
pulisher
Nov 27, 2023

Immutep LimitedADR (IMMP) Price Target Increased by 5.10% to 2.59 - Nasdaq

Nov 27, 2023
pulisher
Dec 23, 2022

Immutep Announces Successful Meeting with the FDA on - GlobeNewswire

Dec 23, 2022
pulisher
Dec 06, 2022

Immutep Announces GMP Manufacturing Process Developed for - GlobeNewswire

Dec 06, 2022
pulisher
Dec 16, 2021

ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - FinancialContent

Dec 16, 2021
pulisher
Apr 08, 2021

FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - targetedonc.com

Apr 08, 2021
pulisher
Dec 14, 2020

72 Biggest Movers From Friday - Benzinga

Dec 14, 2020
pulisher
Jan 10, 2020

Immutep Limited Share Price ADR each Representing 10 Shares - Hargreaves Lansdown

Jan 10, 2020
pulisher
Aug 31, 2018

Immutep valuation increased 16% to $510 million by Edison Investment Research - Proactive financial news

Aug 31, 2018
pulisher
Feb 03, 2018

Technical Analysis of Immutep Ltd Sponsored ADR (NASDAQ:IMMP) - TradingView

Feb 03, 2018
pulisher
Dec 29, 2017

IMM Stock Price and Chart — ASX:IMM - TradingView

Dec 29, 2017
pulisher
Dec 08, 2017

IMMP Stock Price | Immutep Ltd. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch

Dec 08, 2017
pulisher
Dec 05, 2017

Prima BioMed (IMMP) Stock Price, News & Analysis - MarketBeat

Dec 05, 2017
pulisher
Dec 03, 2017

IMMP Stock Price and Chart — NASDAQ:IMMP - TradingView

Dec 03, 2017
pulisher
Sep 26, 2017

Zai Lab Limited (ZLAB) stock price, news, quote and history - Yahoo Finance UK

Sep 26, 2017
pulisher
May 14, 2017

Prima BioMed Share Price | NASDAQ IMMP Stock - Investing.com Australia

May 14, 2017
pulisher
May 13, 2017

Prima BioMed Stock Price Today | NASDAQ: IMMP Live - Investing.com

May 13, 2017
pulisher
Jan 27, 2017

Immutep Ltd Share Price | ASX IMM Stock - Investing.com Australia

Jan 27, 2017

Immutep Limited Adr Stock (IMMP) Financials Data

There is no financial data for Immutep Limited Adr (IMMP). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$39.16
price down icon 1.10%
$100.48
price down icon 1.00%
$32.03
price up icon 1.10%
$95.99
price down icon 0.77%
biotechnology ONC
$331.27
price down icon 1.95%
$205.04
price down icon 0.84%
Cap:     |  Volume (24h):